Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for treating type 2 diabetes mellitus
No bueno, folks
Its front-and-center in a lot of employees lives. Access bonus Workspan Daily Plus+ content on this subject: Increasing Demand Poses Expensive Deliberations Among the nearly 300 employers surveyed by the IFEBP for a recent study, 34% are now covering GLP-1 drugs for both diabetes management and weight loss, up 8 percentage points from 12 months ago
Ipamorelin : Fewer side effects, with minimal impact on cortisol and prolactin
Product selection should reflect formulation quality, testing, tolerance and individual need rather than product availability or marketing category
Ramalingam V, Varadhan P, Fu H-C, Kim H, Zhang D, Chen S et al (2019) Heteroatom-mediated interactions between ruthenium single atoms and an MXene support for efficient hydrogen evolution